Dilated cardiomyopathy and aldosteronoma: a causal link?

The aim of this study is to reveal the causal relationship between dilated cardiomyopathy and aldosteronoma. A 44‐year‐old male dilated cardiomyopathy patient with aldosteronoma, who demonstrated a worse cardiac function after 1 year therapy with optimized dosage of sacubirtil/valsartan, furosemide,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiyu, Yang, Jin, Li, Yueliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083418/
https://www.ncbi.nlm.nih.gov/pubmed/31856419
http://dx.doi.org/10.1002/ehf2.12579
_version_ 1783508529759387648
author Zhang, Jiyu
Yang, Jin
Li, Yueliang
author_facet Zhang, Jiyu
Yang, Jin
Li, Yueliang
author_sort Zhang, Jiyu
collection PubMed
description The aim of this study is to reveal the causal relationship between dilated cardiomyopathy and aldosteronoma. A 44‐year‐old male dilated cardiomyopathy patient with aldosteronoma, who demonstrated a worse cardiac function after 1 year therapy with optimized dosage of sacubirtil/valsartan, furosemide, metoprolol, and spironolactone. The patient shows a promising prognosis after aldosteronoma removal procedure. Aldosteronoma may cause dilated cardiomyopathy. We assume that the optimal treatment for aldosteronoma‐induced dilated cardiomyopathy is surgical removal combined with drugs.
format Online
Article
Text
id pubmed-7083418
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70834182020-03-24 Dilated cardiomyopathy and aldosteronoma: a causal link? Zhang, Jiyu Yang, Jin Li, Yueliang ESC Heart Fail Case Report The aim of this study is to reveal the causal relationship between dilated cardiomyopathy and aldosteronoma. A 44‐year‐old male dilated cardiomyopathy patient with aldosteronoma, who demonstrated a worse cardiac function after 1 year therapy with optimized dosage of sacubirtil/valsartan, furosemide, metoprolol, and spironolactone. The patient shows a promising prognosis after aldosteronoma removal procedure. Aldosteronoma may cause dilated cardiomyopathy. We assume that the optimal treatment for aldosteronoma‐induced dilated cardiomyopathy is surgical removal combined with drugs. John Wiley and Sons Inc. 2019-12-19 /pmc/articles/PMC7083418/ /pubmed/31856419 http://dx.doi.org/10.1002/ehf2.12579 Text en © 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Report
Zhang, Jiyu
Yang, Jin
Li, Yueliang
Dilated cardiomyopathy and aldosteronoma: a causal link?
title Dilated cardiomyopathy and aldosteronoma: a causal link?
title_full Dilated cardiomyopathy and aldosteronoma: a causal link?
title_fullStr Dilated cardiomyopathy and aldosteronoma: a causal link?
title_full_unstemmed Dilated cardiomyopathy and aldosteronoma: a causal link?
title_short Dilated cardiomyopathy and aldosteronoma: a causal link?
title_sort dilated cardiomyopathy and aldosteronoma: a causal link?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083418/
https://www.ncbi.nlm.nih.gov/pubmed/31856419
http://dx.doi.org/10.1002/ehf2.12579
work_keys_str_mv AT zhangjiyu dilatedcardiomyopathyandaldosteronomaacausallink
AT yangjin dilatedcardiomyopathyandaldosteronomaacausallink
AT liyueliang dilatedcardiomyopathyandaldosteronomaacausallink

Ejemplares similares